NEW YORK (TheStreet) -- GW Pharmaceuticals
(GWPH) shares are spiking, up 8.1% to $103.98, on Monday after analysts at Piper Jaffray
(PJC) drastically increased its price target to $147 from $97.
The improved valuation stems from an analyst's evaluation of the U.K. based pharmaceutical company's cannabinoid based epilepsy treatment, Epidolex.
Analysts Dr. Joshua Schimmer believes that the drug is a "highly attractive" treatment for children suffering from Dravet Syndrome, as children treated with it have fewer seizures and can take lower doses of other medicines.
Must Read: Warren Buffett's 25 Favorite Stocks
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV